Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 13/20 | 0.65 |
| ▸ | EZH1 | Q92800 | 11/20 | 0.51 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.51 |
| ▸ | EED | O75530 | 2/20 | 0.51 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.51 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.51 |
| ▸ | RBBP7 | Q16576 | 2/20 | 0.51 |
| ▸ | AEBP2 | Q6ZN18 | 2/20 | 0.51 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17734368 | 0.94 | EZH2 (0.73) | EZH2EZH1PRMT3EEDRBBP4 | |
| SCHEMBL23863675 | 0.91 | EZH2 (0.53) | EZH2EZH1PRMT3EEDRBBP4 | |
| SCHEMBL23863692 | 0.84 | EZH2 (0.52) | EZH2EZH1PRMT3EEDRBBP4 | |
| SCHEMBL23863673 | 0.83 | EZH2 (0.61) | EZH2EZH1PRMT3EEDRBBP4 | |
| SCHEMBL17734376 | 0.82 | EZH2 (0.80) | EZH2EZH1PRMT3EEDRBBP4 | |
| SCHEMBL23863720 | 0.79 | EZH2 (0.88) | EZH2EZH1PRMT3EEDRBBP4 | |
| SCHEMBL17734431 | 0.79 | EZH2 (1.00) | EZH2EZH1PRMT3EEDRBBP4 | |
| SCHEMBL29408698 | 0.79 | EZH2 (1.00) | EZH2EZH1PRMT3EEDRBBP4 | |
| SCHEMBL17734355 | 0.78 | EZH2 (0.89) | EZH2EZH1PRMT3EEDRBBP4 | |
| SCHEMBL17734367 | 0.78 | EZH2 (0.59) | EZH2EZH1PRMT3EEDRBBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885343-A1 | INDOLE COMPOUNDS AS EZH2 INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |